FDA clears new drug application for CAR T-cell therapy in SLE with lupus nephritis

The FDA has cleared an investigational new drug application for an allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of systemic lupus erythematosus with lupus nephritis, according to the manufacturer.
The therapy, developed by Atara Biotherapeutics and currently known as ATA3219, is based on the company’s novel allogeneic Epstein-Barr virus T-cell platform and targets CD19+ relapsed or refractory B-cell malignancies. An investigational new drug application for ATA3219 was previously cleared in non-Hodgkin’s lymphoma, according to a press release from

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart